Evaluate the Efficacy and Safety of TF0023 in Treatments for COVID-19 in Hospitalized Adults
Status:
Not yet recruiting
Trial end date:
2023-06-30
Target enrollment:
Participant gender:
Summary
Techfields Inc. is developing a new investigational prodrug as a topical spray, indicated for
relief of the signs and symptoms of ARDS and pneumonia caused by COVID-19. This is a Phase 2,
Multicenter, Randomized, Double-blind (Within Dose), Placebo-controlled, Parallel-group, and
Dose-range-finding Study to Evaluate the Efficacy and Safety of Active drug Versus Placebo in
Treatments for COVID-19 in Hospitalized Adults, relieving of the signs and symptoms of acute
respiratory distress syndrome (ARDS) and pneumonia caused by coronavirus disease 2019
(COVID-19).